Recent Updates
Recently added Catalysts

Lupus Nephritis: 5 biotech companies with clinical-stage programmes

Immunology & InflammationOrphan cornerData as of 2026-09-04

Competitors5in the clinic
Median market cap$516Muniverse median $1.20B
Allocated capital$589M$2.2B competing
Phase 3 or filed02 mid, 3 early
Pure plays0this indication only
Capital rank195/299crowding rank 38

Lupus Nephritis sits in the orphan corner of the map: 5 developers, none of them large, with a median market cap of $516M against a $1.20B universe median.

A thin field of small caps usually means a narrow addressable population, so the whole field can be repriced by one readout or one financing.

No one owns the field: the largest company, AUTL, holds only 28% of the $2.2B competing here.

$589M of allocated capital sits in Lupus Nephritis, ranking it 195th of 299 indications by the money committed to it.

Companies developing drugs for Lupus Nephritis 5

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
AUTLAutolus TherapeuticsObecabtagene autoleucelPhase 21$610MNo3 31 Dec 2026
FATEFate TherapeuticsFT819Phase 21$290MNo3 30 Jun 2027
ARTVArtiva BiotherapeuticsAB-101Phase 11$544MNo4 31 Dec 2028
KYTXKyverna TherapeuticsKYV-101 anti-CD19 CAR-T cell therapyPhase 14$516MNo5 31 Dec 2026
NKTXNkartaNKX019Phase 11$200MNo4 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. AUTL holds 28% of the $2.2B competing in this indication.

Why Lupus Nephritis is a orphan corner

A thin field of small caps. Few competitors, none of them large.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Lupus Nephritis has 5 competitors and a median of $516M.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Systemic Sclerosis4 companies · $582M · median $540MOrphan cornerInflammatory Bowel Disease1 company · $609M · median $3.0BUncontestedIgG4 Related Disease1 company · $536M · median $2.1BUncontestedPsoriatic Arthritis1 company · $646M · median $1.3BUncontestedXerostomia1 company · $671M · median $1.3BUncontestedChronic Granulomatous Disease1 company · $673M · median $673MUncontestedAcne1 company · $673M · median $673MUncontestedComplement 3 Glomerulopathy1 company · $461M · median $1.4BUncontested

Lupus Nephritis pipeline questions

Which biotech companies are developing drugs for Lupus Nephritis?

Autolus Therapeutics (AUTL, Obecabtagene autoleucel, Phase 2); Fate Therapeutics (FATE, FT819, Phase 2); Artiva Biotherapeutics (ARTV, AB-101, Phase 1); Kyverna Therapeutics (KYTX, KYV-101 anti-CD19 CAR-T cell therapy, Phase 1); Nkarta (NKTX, NKX019, Phase 1). Those are the 5 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Lupus Nephritis.

How advanced is the Lupus Nephritis pipeline?

Of the 5 clinical-stage programmes in Lupus Nephritis, 0 are in Phase 3 or filed, 2 are in mid-stage development and 3 are in early-stage development.

How much is the typical Lupus Nephritis biotech company worth?

The median company developing a drug for Lupus Nephritis is worth $516M, against a median of $1.20B across the whole universe. $589M of allocated capital sits in the indication, ranking it 195th of 299.

When is the next Lupus Nephritis catalyst?

The next dated catalyst in Lupus Nephritis is AUTL on 31 Dec 2026. 4 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map